Stanley C. Erck Sells 21,607 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $3.62 on Friday. MaxCyte, Inc. has a 1 year low of $2.45 and a 1 year high of $5.55. The firm has a market capitalization of $379.46 million, a price-to-earnings ratio of -10.34 and a beta of 1.39. The business’s 50 day moving average price is $4.14 and its 200-day moving average price is $4.25.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The firm had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. During the same quarter last year, the firm posted ($0.10) EPS. On average, sell-side analysts expect that MaxCyte, Inc. will post -0.44 earnings per share for the current year.

Institutional Trading of MaxCyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in shares of MaxCyte in the 1st quarter worth $28,000. PNC Financial Services Group Inc. acquired a new stake in shares of MaxCyte during the 4th quarter worth about $29,000. China Universal Asset Management Co. Ltd. increased its position in shares of MaxCyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock worth $83,000 after purchasing an additional 7,898 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after purchasing an additional 4,320 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after purchasing an additional 5,927 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.